MedTrace Logo

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area

NCT00913757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1871

Last updated 2020-05-04

No results posted yet for this study

Summary

Background:

* Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and it has grown more prevalent in the United States.
* More information is needed about the causes and effects of liver cancer, and further research into individuals who are at high risk for developing liver cancer is needed for early diagnosis and prevention.

Objectives:

* To identify genetic factors that may help to explain the aggressiveness of liver cancer.
* To determine if HCC biomarkers exist in blood, urine, and tissue samples.

Eligibility:

* Patients between the ages of 18 and 90 who have been diagnosed with HCC or have a high risk for developing HCC because of fatty liver disease (alcohol-related or non-alcohol-related) or chronic hepatitis B or C.
* Participants will reside in Baltimore City and the surrounding areas.

Design:

* Participants will complete a questionnaire and provide blood and urine samples for testing:
* The questionnaire will include questions about individual and family medical history, tobacco use, and exposure to known factors for liver cancer.
* Blood and urine samples will be collected from all participants after the questionnaire.
* Tumor tissue and healthy tissue will be collected from selected participants if they undergo surgery for their cancer or disease.
* No specific treatment will be offered as part of this protocol, but participants have the option to be treated under different protocols.

Conditions

  • Carcinoma, Hepatocellular
  • Liver Cirrhosis, Alcoholic
  • Hepatitis, Alcoholic
  • Hepatitis, Chronic
  • Hepatitis, Viral, Human

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Xin Wang, M.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-01
Primary Completion
2020-05-01
Completion
2020-05-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913757 on ClinicalTrials.gov